Supernus Pharmaceuticals Q3 2023 EPS $(0.29) Down From $(0.03) YoY, Revenue $153.9M Beats $143.387M Estimate
Portfolio Pulse from Benzinga Newsdesk
Supernus Pharmaceuticals reported Q3 2023 earnings per share (EPS) of $(0.29), down from $(0.03) year over year (YoY). However, the company's revenue of $153.9M beat the estimate of $143.387M.
November 08, 2023 | 9:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Supernus Pharmaceuticals' Q3 2023 EPS fell significantly YoY, but its revenue exceeded estimates.
While the significant drop in EPS is a negative signal, the fact that Supernus Pharmaceuticals managed to beat revenue estimates could offset this to some extent. Therefore, the short-term impact on the stock price could be neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100